TNP 2198

Drug Profile

TNP 2198

Alternative Names: TNP2198

Latest Information Update: 14 Sep 2016

Price : $50

At a glance

  • Originator Cumbre Pharmaceuticals
  • Developer TenNor Therapeutics
  • Class Antibacterials
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Bacterial infections

Most Recent Events

  • 14 Sep 2016 TenNor Therapeutics has patent protection for dual-acting molecules, including TNP 2198 in USA (TenNor Therapeutics website; September 2016)
  • 09 Sep 2016 Early research in Bacterial infections in China (unspecified route) (TenNor Therapeutics pipeline; September 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top